Asian Penny Stocks To Watch In January 2026

As 2026 begins, Asian markets are capturing attention with their dynamic movements, particularly as investors navigate the broader global economic landscape. Penny stocks, though often seen as a niche investment area, continue to hold potential for those seeking value and growth in smaller or newer companies. Despite being an older term, penny stocks can still offer significant opportunities when backed by strong financial health; here we explore a few that stand out for their promising attributes.

Top 10 Penny Stocks In Asia

Name	Share Price	Market Cap	Rewards & Risks
Oiltek International (SGX:HQU)	SGD0.67	SGD287.43M	✅ 4 ⚠️ 2 View Analysis >
Lever Style (SEHK:1346)	HK$1.46	HK$903.04M	✅ 4 ⚠️ 1 View Analysis >
Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)	THB2.40	THB1.01B	✅ 3 ⚠️ 3 View Analysis >
TK Group (Holdings) (SEHK:2283)	HK$2.53	HK$2.1B	✅ 4 ⚠️ 1 View Analysis >
Atlantic Navigation Holdings (Singapore) (Catalist:5UL)	SGD0.109	SGD57.06M	✅ 2 ⚠️ 3 View Analysis >
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)	SGD3.62	SGD14.25B	✅ 5 ⚠️ 1 View Analysis >
NagaCorp (SEHK:3918)	HK$4.73	HK$20.92B	✅ 5 ⚠️ 1 View Analysis >
Livestock Improvement (NZSE:LIC)	NZ$1.00	NZ$137.01M	✅ 2 ⚠️ 5 View Analysis >
Bosideng International Holdings (SEHK:3998)	HK$4.48	HK$52.01B	✅ 4 ⚠️ 2 View Analysis >
Scott Technology (NZSE:SCT)	NZ$2.84	NZ$237.15M	✅ 3 ⚠️ 1 View Analysis >

Click here to see the full list of 955 stocks from our Asian Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Viva Biotech Holdings (SEHK:1873)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Viva Biotech Holdings is an investment holding company that offers structure-based drug discovery services to biotechnology and pharmaceutical clients globally, with a market cap of HK$4.09 billion.

Operations: The company's revenue is primarily derived from its Drug Discovery Services, which generated CN¥853.38 million, and its Contract Development Manufacture Organisation (CDMO) and Commercialisation Services, contributing CN¥995.92 million, while Viva Bioinnovator added CN¥15.58 million.

Market Cap: HK$4.09B

Viva Biotech Holdings has recently become profitable, marking a significant shift in its financial trajectory. The company's short-term assets of CN¥1.7 billion comfortably cover its short-term liabilities of CN¥991.7 million, though they fall short against long-term liabilities of CN¥2 billion. Its debt is well-managed with a satisfactory net debt to equity ratio of 5.7% and operating cash flow covering 31.1% of its debt. Despite stable weekly volatility at 8%, the anticipated earnings decline by an average of 35.1% annually over the next three years presents a challenge, although revenue is expected to grow by 15.72% per year.

• Take a closer look at Viva Biotech Holdings' potential here in our financial health report.
• Understand Viva Biotech Holdings' earnings outlook by examining our growth report.

Uju Holding (SEHK:1948)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Uju Holding Limited is an investment holding company offering digital marketing services and live-streaming e-commerce in the People’s Republic of China, with a market cap of approximately HK$2.75 billion.

Operations: The company's revenue is derived from its All-In-One Online Marketing Solutions Services, which generated CN¥10.30 billion.

Market Cap: HK$2.75B

Uju Holding Limited's revenue from its digital marketing services reached CN¥10.3 billion, reflecting robust growth driven by strategic partnerships and expansion efforts. The company's earnings grew 26.7% over the past year, surpassing industry averages despite a low return on equity of 7.7%. Uju's financial stability is supported by more cash than debt and strong coverage of liabilities with short-term assets of CN¥5 billion against long-term liabilities of CN¥2.9 million. Recent leadership changes include the resignation of an executive director, indicating potential shifts in strategic direction as the company continues to expand its market presence.

• Dive into the specifics of Uju Holding here with our thorough balance sheet health report.
• Assess Uju Holding's future earnings estimates with our detailed growth reports.

Greentown Service Group (SEHK:2869)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Greentown Service Group Co. Ltd., along with its subsidiaries, offers residential property management services in the People's Republic of China and internationally, with a market cap of HK$14.59 billion.

Operations: The company generates revenue through three primary segments: Property Services (CN¥13.02 billion), Consulting Services (CN¥2.42 billion), and Community Living Services excluding Technology Services (CN¥2.65 billion).

Market Cap: HK$14.59B

Greentown Service Group's financial health is underscored by its strong balance sheet, with short-term assets of CN¥13.6 billion exceeding both short and long-term liabilities. The company has shown a significant improvement in earnings growth over the past year at 17.1%, surpassing industry averages, while maintaining high-quality earnings and stable weekly volatility. Recent strategic moves include a share buyback program aimed at enhancing shareholder value and the resignation of a long-serving non-executive director, which marks a completed leadership transition ensuring ongoing stability within its management structure.

• Get an in-depth perspective on Greentown Service Group's performance by reading our balance sheet health report here.
• Gain insights into Greentown Service Group's outlook and expected performance with our report on the company's earnings estimates.

Next Steps

• Unlock our comprehensive list of 955 Asian Penny Stocks by clicking here.
• Curious About Other Options? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 28 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com